Please wait a minute...
European Journal of Gynaecological Oncology  2018, Vol. 39 Issue (5): 821-824    DOI: 10.12892/ejgo3920.2018
Case Report Previous articles | Next articles
Prolonged stable disease using pazopanib in recurrent and refractory uterine leiomyosarcoma: a proposal of “pazopanib beyond progression”
H. Ishibashi1, M. Takano2, *(), M. Miyamoto1, T. Aoyama1, T. Yoshikawa2, K. Furuya1
1 Departments of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Japan
2 Departments of Clinical Oncology, National Defense Medical College, Tokorozawa, Japan
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
Background: To date, there is no standard therapy in patients with recurrent or refractory uterine leiomyosarcoma (LMS). A case with LMS that achieved prolonged stable disease using pazopanib beyond progression (PBP) is reported. Case Report: A 49-year-old patient with recurrent and refractory LMS that achieved long-term stable disease is reported. The patient had previously received three regimens before pazopanib therapy: combination chemotherapy with ifosfamide, doxorubicin, and cisplatin (IAP), gemcitabine monotherapy, and combination therapy with bevacizumab, temozolomide, and cabozantinib. Subsequently, oral administration of pazopanib was initiated at a dose of 400 mg daily. At the third week, the dose was reduced to 200 mg daily due to grade 1 hypothyroidism. At the ninth week, a new lesion in liver was detected; however, continuation of pazopanib was selected. At the 15th week, the patient developed moderate genital bleeding and received palliative radiotherapy (30 Gy) in addition to pazopaznib. The patient occasionally developed toxicities such as hypetension and diarrhea, which were manageable. At the 59th week, her general condition was suddenly worsened due to disease progression, and pazopanib treatment was discontinued. During the period of pazopanib, recurrent tumors showed stable disease, in spite of occurrence of new lesion at liver. Subsequently, the patient died of the disease 16 months after the initiation of pazopanib monotherapy. Conclusion: PBP could be a candidate for the patients with recurrent or refractory LMS.
Key words:  Uterus      Leiomyosarcoma      Pazopanib beyond progression (PBP)     
Published:  10 October 2018     
*Corresponding Author(s):  M. TAKANO     E-mail:  mastkn@ndmc.ac.jp

Cite this article: 

H. Ishibashi, M. Takano, M. Miyamoto, T. Aoyama, T. Yoshikawa, K. Furuya. Prolonged stable disease using pazopanib in recurrent and refractory uterine leiomyosarcoma: a proposal of “pazopanib beyond progression”. European Journal of Gynaecological Oncology, 2018, 39(5): 821-824.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo3920.2018     OR     https://ejgo.imrpress.com/EN/Y2018/V39/I5/821

[1] Joseph J. Noh, Sir-Yeon Hong, Byeong-gie Kim. Malignant perivascular epithelioid cell tumor (PEComa) of uterus: A case report with literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 495-499.
[2] Ming Wang, Shi-Hui Meng, Yu-Mei Wu. Ovarian conservation without postoperative radiation improved survival outcomes in patients with stage i uterine leiomyosarcoma[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 422-431.
[3] B. Serdar, K. Meral, S. Ugur, D. Binnaz, D. Namık. Intrapelvic low grade leiomyosarcoma with good prognosis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 468-470.
[4] Sang Wook Yi. Malignant mixed mesonephric tumor arising in mesonephric carcinoma: a case report with complete remission after concurrent chemoradiation therapy[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 320-322.
[5] K. Sonoda, M. Nogami, K. Kodama, Y. Oda, K. Kato. Re-evaluation of preoperative endometrial smears for the cytodiagnosis of uterine leiomyosarcoma[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 167-170.
[6] Z. Zheng, Z.H. Han, Z.T. Li, X.H. Wu. The impact of laparoscopic surgical treatments on oncologic outcome of Stage I uterine leiomyosarcoma[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 977-981.
[7] N. Okabe, M. Fujiwara, M. Mochizuki, K. Ohtsuka, Y. Nishigaya, Y. Kobayashi, H. Kamma. CD34-positive uterine lipoleiomyoma in a postmenopausal woman with chronic glomerulonephritis[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1060-1063.
[8] J. Klat, O. Simetka, C. Povysil. Cervical leiomyosarcoma treated by radical laparoscopic approach: a case report[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1093-1095.
[9] S. Furukawa, K. Hasegawa, Y. Nozawa, Y. Endo, M. Takata, F. Yoshida-Saito, S. Nakamura, R. Yamauchi. A rare case of primary ovarian leiomyosarcoma[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 870-874.
[10] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879-882.
[11] Z. Fasoulakis, H. Achouhan, S. Kalagasidou, P. Kadari, A. Pagkalos, P. Simeonidis, E.N. Kontomanolis. A review on uterine sarcomas and a brief report on the role of the notch pathway[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 521-529.
[12] A. Mladěnka, P. Mladěnka, O. Simetka, J. Klát. Intra-operative and postoperative complications depend on operating approach and body mass index in patients with malignant uterus body neoplasm[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 593-598.
[13] Haiyang Jiang, Luyun Qu, Zenghui Li, Xiaohong Li, Jing Wang, Jianqing Hou. Exploring biomarkers for uterine leiomyosarcoma via combination of iMDM algorithm and pathway enrichment analysis[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 268-274.
[14] Mehmet Tunc, Yusuf Aytac Tohma, Hanifi Sahin, Huseyin Akilli, Latife Atasoy Karakas, Ozden Altundag, Ali Haberal, Ali Ayhan. Fertility sparing in uterine sarcomas: single center experience of 13 patients[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 305-310.
[15] L.M. Langermans, A. Salajan, C. Riera. Retroperitoneal benign leiomyoma is a challenging diagnosis in gynecology: report of two cases[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 318-320.
No Suggested Reading articles found!